JP2025514649A5 - - Google Patents
Info
- Publication number
- JP2025514649A5 JP2025514649A5 JP2024559221A JP2024559221A JP2025514649A5 JP 2025514649 A5 JP2025514649 A5 JP 2025514649A5 JP 2024559221 A JP2024559221 A JP 2024559221A JP 2024559221 A JP2024559221 A JP 2024559221A JP 2025514649 A5 JP2025514649 A5 JP 2025514649A5
- Authority
- JP
- Japan
- Prior art keywords
- mol
- composition
- lipids
- steroids
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2022/059023 | 2022-04-05 | ||
| PCT/EP2022/059023 WO2023193892A1 (en) | 2022-04-05 | 2022-04-05 | Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same |
| PCT/EP2023/059066 WO2023194508A1 (en) | 2022-04-05 | 2023-04-05 | Nucleic acid compositions comprising a multivalent anion, such as an inorganic polyphosphate, and methods for preparing, storing and using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025514649A JP2025514649A (ja) | 2025-05-09 |
| JP2025514649A5 true JP2025514649A5 (https=) | 2026-04-13 |
Family
ID=81307329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024559221A Pending JP2025514649A (ja) | 2022-04-05 | 2023-04-05 | 無機ポリリン酸などの多価アニオンを含む核酸組成物ならびにその製造、保存および使用のための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250222132A1 (https=) |
| EP (1) | EP4504158A1 (https=) |
| JP (1) | JP2025514649A (https=) |
| CN (1) | CN119278031A (https=) |
| AU (1) | AU2023248681A1 (https=) |
| CA (1) | CA3246753A1 (https=) |
| IL (1) | IL315673A (https=) |
| WO (2) | WO2023193892A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023413766A1 (en) | 2022-12-23 | 2025-05-29 | Biontech Delivery Technologies Gmbh | Composition |
| WO2025133105A1 (en) | 2023-12-21 | 2025-06-26 | Biontech Delivery Technologies Gmbh | Compositions and methods |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| ES2336887T5 (es) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediadores de interferencia por ARN específicos de secuencias de ARN |
| US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| EP1900753B1 (en) | 2002-11-08 | 2017-08-09 | Ablynx N.V. | Method of administering therapeutic polypeptides, and polypeptides therefor |
| HUE027902T2 (en) | 2004-02-09 | 2016-11-28 | Human Genome Sciences Inc Corp Service Company | Albumin fusion proteins |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| CN101511868B (zh) | 2006-07-24 | 2013-03-06 | 比奥雷克西斯制药公司 | 毒蜥外泌肽融合蛋白 |
| AU2007293614A1 (en) | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| WO2009083804A2 (en) | 2007-12-27 | 2009-07-09 | Novartis Ag | Improved fibronectin-based binding molecules and their use |
| EA201001734A1 (ru) | 2008-05-02 | 2011-10-31 | Новартис Аг | Улучшенные связывающие молекулы на основе фибронектина и их применение |
| EP2493871B1 (en) | 2009-10-30 | 2014-09-03 | Domain Therapeutics | Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| EP2556087A1 (en) | 2010-04-09 | 2013-02-13 | Novozymes Biopharma DK A/S | Albumin derivatives and variants |
| EP2558491B1 (en) | 2010-04-13 | 2018-07-04 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind pcsk9 |
| EP2758436B1 (en) | 2011-09-23 | 2019-06-12 | Universität Stuttgart | Serum half-life extension using immunoglobulin binding domains |
| EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| US9656233B2 (en) * | 2015-01-16 | 2017-05-23 | Encapsys, Llc | Reversible microcapsule filter cake |
| AU2016253972B2 (en) | 2015-04-27 | 2020-01-02 | Acuitas Therapeutics Inc. | Nucleoside-modified RNA for inducing an adaptive immune response |
| HRP20230209T1 (hr) * | 2015-10-28 | 2023-04-14 | Acuitas Therapeutics Inc. | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
| SI3445850T1 (sl) | 2016-04-22 | 2021-12-31 | BioNTech SE | Postopki za zagotavljanje enoverižne RNA |
| EP3468610A1 (en) * | 2016-06-09 | 2019-04-17 | OPKO Biologics Ltd. | Long-acting oxyntomodulin formulation and methods of producing and administering same |
| CA3040337A1 (en) | 2016-10-26 | 2018-05-03 | Curevac Ag | Lipid nanoparticle mrna vaccines |
| KR20200143391A (ko) | 2018-03-15 | 2020-12-23 | 비온테크 알엔에이 파마슈티컬스 게엠베하 | 5'-캡-트리뉴클레오티드- 또는 고차의 올리고뉴클레오티드 화합물 및 이들의 rna 안정화, 단백질 발현 및 치료에서의 사용 |
| US12419965B2 (en) * | 2018-10-01 | 2025-09-23 | BioNTech SE | RNA particles comprising polysarcosine |
| CN115335084A (zh) * | 2020-03-25 | 2022-11-11 | 生物技术公司 | 包含聚肌氨酸的rna颗粒 |
-
2022
- 2022-04-05 WO PCT/EP2022/059023 patent/WO2023193892A1/en not_active Ceased
-
2023
- 2023-04-05 AU AU2023248681A patent/AU2023248681A1/en active Pending
- 2023-04-05 US US18/853,663 patent/US20250222132A1/en active Pending
- 2023-04-05 CN CN202380032503.4A patent/CN119278031A/zh active Pending
- 2023-04-05 CA CA3246753A patent/CA3246753A1/en active Pending
- 2023-04-05 EP EP23718732.3A patent/EP4504158A1/en active Pending
- 2023-04-05 JP JP2024559221A patent/JP2025514649A/ja active Pending
- 2023-04-05 IL IL315673A patent/IL315673A/en unknown
- 2023-04-05 WO PCT/EP2023/059066 patent/WO2023194508A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023549266A5 (https=) | ||
| JP2023552678A5 (https=) | ||
| JP2025514649A5 (https=) | ||
| JP2024534697A5 (https=) | ||
| US4235871A (en) | Method of encapsulating biologically active materials in lipid vesicles | |
| US4241046A (en) | Method of encapsulating biologically active materials in lipid vesicles | |
| ES2289079T3 (es) | Liposomas anfotericos y su utilizacion. | |
| CN116672316B (zh) | 一种核酸-脂质纳米颗粒冻干制剂及其制备方法 | |
| WO2024046448A1 (en) | Lyophilized formulations and liquid formulations of lipid nanoparticles | |
| US5230899A (en) | Methods and compositions for making liposomes | |
| IE862103L (en) | Liposome compositions | |
| JP2020532546A5 (https=) | ||
| HK1004530B (en) | Method and composition for making liposomes | |
| JP2024527940A5 (https=) | ||
| TWI262798B (en) | Liposome and drug deliver system | |
| CN116236565B (zh) | 适合于肌注给药的核酸-脂质纳米颗粒、制剂及其应用 | |
| JP2024514364A5 (https=) | ||
| JP2025525497A (ja) | 脂質製剤 | |
| CN120271486A (zh) | 一类可用于活性分子递送的可降解脂质体及其脂质纳米粒子 | |
| US20040247659A1 (en) | (Ester)-lysolecithins in liposomes | |
| US20080088046A1 (en) | Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome | |
| WO2014065245A1 (ja) | 弱酸性ｐＨ応答性ペプチド及び該ペプチドを含むリポソーム | |
| TW202530174A (zh) | 用於遞送的脂質化合物及脂質奈米顆粒 | |
| JP4305615B2 (ja) | ポリアミドアミンデンドロンを含む遺伝子導入剤組成物 | |
| Bulbake et al. | Liposomal drug delivery system and its clinically available products |